Cargando…
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres
SHetA2 is a small molecule flexible heteroarotinoid (Flex-Het) with promising cancer prevention and therapeutic activity. Extensive preclinical testing documented lack of SHetA2 toxicity at doses 25 to 150 fold above effective doses. Knowledge of the SHetA2 molecular target(s) that mediate(s) the me...
Autores principales: | Benbrook, Doris Mangiaracina, Nammalwar, Baskar, Long, Andrew, Matsumoto, Hiroyuki, Singh, Anil, Bunce, Richard A., Berlin, K. Darrell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045313/ https://www.ncbi.nlm.nih.gov/pubmed/24254390 http://dx.doi.org/10.1007/s10637-013-0041-x |
Ejemplares similares
-
SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention
por: Benbrook, Doris Mangiaracina
Publicado: (2022) -
Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
por: Chandra, Vishal, et al.
Publicado: (2021) -
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
por: Myers, Tashanna, et al.
Publicado: (2008) -
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice
por: Benbrook, Doris M., et al.
Publicado: (2017) -
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2
por: Sharma, Ankur, et al.
Publicado: (2018)